Goldman Sachs
QNCX icon

Goldman Sachs’s Quince Therapeutics QNCX Stock Holding History

Goldman Sachs’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-25
Closed -$458K – 6657
2021
Q3 		$458K Hold
25
– – ﹤0.01% 5249
2021
Q2 		$265K Buy
+25
New +$210K ﹤0.01% 5594

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Goldman Sachs's QNCX Position: Q1 2026 in Review

Goldman Sachs reduced its Quince Therapeutics (QNCX) stake by 93% in Q1 2026, selling an estimated $214K and leaving 80 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #6421.

Goldman Sachs first reported a position in QNCX in Q2 2019 and has held it in 15 quarters since. The position peaked at $3.74M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Goldman Sachs held 80 shares of Quince Therapeutics worth $1.63K as of Q1 2026.
  • Goldman Sachs sold 1,068 Quince Therapeutics shares in Q1 2026, an estimated $214K.
  • Quince Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #6421 holding.
  • Goldman Sachs first reported a position in Quince Therapeutics in Q2 2019 and has held it in 15 quarters since.
  • Goldman Sachs's Quince Therapeutics position peaked at $3.74M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.